当前位置： SCI文献检索 > DIABETES CARE期刊下所有文献 > A randomized placebo-controlled trial of repaglinide in the treatment of type 2 diabetes.

A randomized placebo-controlled trial of repaglinide in the treatment of type 2 diabetes.

Abstract：

OBJECTIVE:The objective of the study was to assess the efficacy and safety of repaglinide compared with placebo in the treatment of patients with type 2 diabetes. RESEARCH DESIGN AND METHODS:This was a phase II multicenter, double-blind, placebo-controlled, randomized, dose-adjustment and maintenance trial. After screening and a 2-week washout period, 99 patients were randomized to receive either repaglinide (n = 66) or placebo (n = 33). Patients underwent 6 weeks of dose adjustment followed by 12 weeks of dose maintenance. Fasting and stimulated glycosylated hemoglobin (HbA1c), plasma glucose, insulin, and C-peptide were measured at predetermined intervals. Adverse events and hypoglycemic episodes were recorded. RESULTS:From baseline to last visit, mean HbA1c decreased from 8.5 to 7.8% in patients treated with repaglinide and increased from 8.1 to 9.3% in patients receiving placebo, with a statistically significant difference of - 1.7% (P < 0.0001) between treatment groups at the last visit. Mean fasting plasma glucose and postprandial glucose increased in patients receiving placebo and decreased in patients treated with repaglinide, with statistically significant (P < 0.01) differences between groups at the last visit. Concentrations of fasting and postprandial insulin and C-peptide were lower at the last visit compared with baseline for patients treated with placebo and higher for patients treated with repaglinide, and the differences between groups were statistically significant (P < 0.05). Overall, repaglinide was well tolerated. CONCLUSIONS:This study demonstrated that repaglinide was safe and efficacious in lowering blood glucose concentrations. In addition to overall improvement in glycemic control noted with repaglinide in both sulfonylurea-treated patients and oral hypoglycemic agent-naive patients, repaglinide had a potent glucose-lowering effect in the postprandial period.

journal_name

Diabetes Care

journal_title

Diabetes care

authors

Goldberg RB,Einhorn D,Lucas CP,Rendell MS,Damsbo P,Huang WC,Strange P,Brodows RG

doi

10.2337/diacare.21.11.1897

subject

Has Abstract

pub_date

1998-11-01 00:00:00

pages

1897-903

issue

eissn

0149-5992

issn

1935-5548

journal_volume

pub_type

临床试验,杂志文章,多中心研究,随机对照试验

在线工具

A randomized placebo-controlled trial of repaglinide in the treatment of type 2 diabetes.